Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Assets: 2012-2024

Historic Current Assets for RedHill Biopharma (RDHL) over the last 12 years, with Dec 2024 value amounting to $11.9 million.

  • RedHill Biopharma's Current Assets fell 20.05% to $12.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.6 million, marking a year-over-year decrease of 20.05%. This contributed to the annual value of $11.9 million for FY2024, which is 26.20% down from last year.
  • RedHill Biopharma's Current Assets amounted to $11.9 million in FY2024, which was down 26.20% from $16.1 million recorded in FY2023.
  • RedHill Biopharma's 5-year Current Assets high stood at $89.2 million for FY2021, and its period low was $11.9 million during FY2024.
  • Over the past 3 years, RedHill Biopharma's median Current Assets value was $16.1 million (recorded in 2023), while the average stood at $38.0 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 32.47% in 2020, then slumped by 81.21% in 2023.
  • RedHill Biopharma's Current Assets (Yearly) stood at $70.5 million in 2020, then climbed by 26.47% to $89.2 million in 2021, then dropped by 3.65% to $85.9 million in 2022, then slumped by 81.21% to $16.1 million in 2023, then fell by 26.20% to $11.9 million in 2024.